Quadruplet regimen demonstrated significantly deeper and more durable responses, higher MRD negativity and improved progression-free survival versus a standard of care Approval marks the twelfth indication for DARZALEX FASPRO ® and fifth in the newly diagnosed setting, underscoring its role as foundational therapy for both newly diagnosed and relapsed/refractory multiple myeloma patients HO...
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson, with support from the Johnson & Johnson (J&J) Foundation, announced that it has donated $100 million of MedTech products since 2020 to help more people around the world access the specialized care they need to live, see and smile. The Company has also planned to contribute an additional $20 million toward programs and impact investments t...
Dividend Kings underperformed SPY in 2025, averaging 4.91% total return versus SPY's 17.72%, though 14 Kings outperformed the index. 2026 began strongly for Dividend Kings, up 4.66% through January 23rd, outpacing SPY's 1.07% gain. Nineteen Dividend Kings appear both potentially undervalued and offer long-term annualized expected returns of at least 10%.
Johnson & Johnson NYSE: JNJ, amid the noise of Trump's Greenland agenda and renewed trade war fears, is quietly executing its healthcare strategy, growing revenue and widening margins, setting its stock up to continue trending higher. A recent earnings release and 2026 guidance update, though strong, triggered a price pullback and a trend-following opportunity.
Johnson & Johnson has increased its dividend for an impressive 63 consecutive years. The company appears to be navigating an expanding patent cliff well.
aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.